Edition:
United States

DiaSorin SpA (DIAS.MI)

DIAS.MI on Milan Stock Exchange

70.15EUR
11:35am EDT
Change (% chg)

€-0.20 (-0.28%)
Prev Close
€70.35
Open
€70.25
Day's High
€70.65
Day's Low
€69.80
Volume
53,923
Avg. Vol
89,264
52-wk High
€72.80
52-wk Low
€49.98

Latest Key Developments (Source: Significant Developments)

Diasorin presents its 2017-2019 industrial plan
Monday, 26 Jun 2017 01:28am EDT 

June 26 (Reuters) - DIASORIN SPA : :DIASORIN PRESENTS ITS 2017-2019 INDUSTRIAL PLAN.DIASORIN CONFIRMS FURTHER DEVELOPMENT OF LIAISON XS.DIASORIN WILL CONTINUE TO LOOK FOR POTENTIAL ACQUISITIONS, FOCUSING ON TARGET THAT WILL ALLOW GROUP TO EXPAND ITS CUSTOMER BASE AND ITS PRESENCE IN STRATEGIC MARKETS.SEES GROWTH IN BOTH IMMUNODIAGNOSTIC AND MOLECULAR DIAGNOSTIC TECHNOLOGIES.SEES FY 2019 REVENUE AT AROUND EUR 735 MILLION, FY 2019 EBITDA BETWEEN EUR 280 MILLION AND EUR 285 MILLION, FY 2019 NET RESULT BETWEEN EUR 155 MILLION AND EUR 160 MILLION.  Full Article

DiaSorin to collaborate with Tecan in platform development
Friday, 23 Jun 2017 01:27am EDT 

June 23 (Reuters) - DIASORIN SPA ::TO COLLABORATE WITH TECAN <<>> IN NEW PLATFORM DEVELOPMENT.UNDER COLLABORATION DIASORIN WILL MAKE USE OF TECAN'S FLUENT LABORATORY AUTOMATION SOLUTION AS ITS NUCLEIC ACID EXTRACTION PLATFORM.  Full Article

Diasorin signs collaboration with QIAGEN to expand LIAISON test menu
Thursday, 22 Jun 2017 11:58am EDT 

June 22 (Reuters) - DIASORIN SPA ::SIGNS COLLABORATION WITH QIAGEN <<>> TO DEVELOP NEW TESTS FOR DIASORIN’S LIAISON FAMILY OF ANALYZERS BASED ON REVIEW AND SELECTION PROCESS INVOLVING QIAGEN’S ASSAY TECHNOLOGIES.  Full Article

DiaSorin launches Liaison androstenedione test
Tuesday, 16 May 2017 04:52am EDT 

May 16 (Reuters) - DIASORIN SPA ::LAUNCHES NEW LIAISON ANDROSTENEDIONE TEST FOR EVALUATION OF ADRENAL AND GONADAL FUNCTIONALITY.LIAISON ANDROSTENEDIONE TEST AVAILABLE WORLDWIDE WITH EXCEPTION OF U.S..ELEVATED ANDROSTENEDIONE LEVELS IN BLOOD ARE ASSOCIATED WITH HORMONE-RELATED DISEASES SUCH AS POLYCYSTIC OVARIAN SYNDROME (PCOS), CONGENITAL ADRENAL HYPERPLASIA (CAH) AND ADRENAL GLAND TUMORS.  Full Article

Diasorin Q1 net profit rises to EUR 32.0 million
Monday, 8 May 2017 11:28am EDT 

May 8 (Reuters) - DIASORIN SPA :Q1 REVENUE EUR 157.5 MILLION VERSUS EUR 124.5 MILLION YEAR AGO.Q1 NET PROFIT EUR 32.9 MILLION VERSUS EUR 24.7 MILLION YEAR AGO.SEES FY 2017 REVENUES GROWTH EQUAL TO +11% AT CER COMPARED WITH 2016.SEES FY 2017 EBITDA GROWTH EQUAL TO +11% AT CER COMPARED WITH 2016.  Full Article

Diasorin receives authorization for distribution of Zika IgM test in Europe
Friday, 21 Apr 2017 10:33am EDT 

April 21 (Reuters) - Diasorin SpA ::Receives authorization for distribution of Zika IgM test in Europe.  Full Article

DiaSorin FY net profit up 12 pct at EUR 112.6 mln, proposes dividend of EUR 0.80/shr
Wednesday, 8 Mar 2017 08:40am EST 

DiaSorin SpA : Proposes cash dividend of 0.80 euro per share, up 23.1 pct versus 2015 . FY net profit 112.6 million euros ($118.70 million) versus 100.5 million euros a year ago . FY revenue 569.3 million euros versus 499.2 million euros a year ago . 2017 guidance, including unit Focus: revenues up around 11 pct at constant exchange rates (CER), compared with 2016 .2017 guidance, including unit Focus: EBITDA up around 11 pct at CER, compared with 2016.  Full Article

DiaSorin launches test Simplexa C. Difficile Direct in the U.S.
Tuesday, 21 Feb 2017 04:31am EST 

DiaSorin SpA : Launches molecular test Simplexa C. Difficile Direct in the United States .Clostridium difficile Infection (CDI) is a cause of antibiotic-associated diarrhea and colitis.  Full Article

DiaSorin launches test Liaison FGF 23 for chronic kidney disease
Thursday, 26 Jan 2017 05:30am EST 

DiaSorin SpA : Launches test Liaison FGF 23, an automated marker for chronic kidney disease .Liaison FGF 23 to be available worldwide with the exception of the U.S..  Full Article

Diasorin Q3 net profit rises to EUR 28.7 mln
Thursday, 10 Nov 2016 07:15am EST 

Diasorin SpA : Reports Q3 net profit 28.7 million euros ($31.21 million)versus 23.2 million euros a year ago . Q3 revenue 147.0 million euros versus 123.2 million euros a year ago .Confirms previous guidance on revenues and EBITDA for 2016.  Full Article

BRIEF-DiaSorin launches test Iam CBFB-MYH11 for acute myeloid leukemia

* LAUNCHES MOLECULAR DIAGNOSTIC TEST IAM CBFB-MYH11 (AVAILABLE WORLDWIDE EXCEPT UNITED STATES) FOR DIAGNOSIS OF ONE OF THE GENETIC CAUSES OF ACUTE MYELOID LEUKEMIA Source text: http://reut.rs/2tZeE1p Further company coverage: (Gdynia Newsroom)